Remedium Lifecare Ltd. , a prominent player in the pharmaceutical supply chain and specialty chemicals sector, has announced significant changes to its leadership team. The company has appointed Mr. Vignesh Laxman Gawde as Whole-Time Director and Mr. Rambhajan Vishwakarma as Independent Director, in a move aimed at enhancing its leadership and promoting growth in the pharmaceutical sector.

Strategic Appointments

The appointments come at a crucial time for Remedium Lifecare as it seeks to accelerate its growth momentum. Mr. Adarsh Munjal, Managing Director of Remedium Lifecare Ltd., expressed confidence in the new appointments, stating, "Mr. Gawde's deep technical expertise in the pharmaceutical field and Mr. Vishwakarma's vast experience in the financial sector will bring a strong strategic balance to our leadership team."

Expertise and Experience

Mr. Gawde, with his extensive background in pharmaceutical research, is expected to focus on strengthening R&D, quality assurance, and innovation. His expertise aligns with Remedium Lifecare's expansion plans across key therapeutic areas, including anti-infectives, cardiovascular, and CNS treatments.

Mr. Vishwakarma's appointment as Independent Director is aimed at enhancing corporate governance, transparency, and financial oversight. His experience in the financial sector is expected to support Remedium Lifecare's financial prudence and growth strategy.

Future Outlook

These strategic appointments underscore Remedium Lifecare's commitment to building a robust, future-ready leadership structure. The company anticipates that the combined experience of Mr. Gawde and Mr. Vishwakarma will drive its next phase of expansion, enhancing R&D capabilities, strengthening operational efficiencies, and deepening market presence across domestic and global geographies.

As Remedium Lifecare continues to evolve in the pharmaceutical and specialty chemicals space, these leadership changes signal the company's focus on innovation, quality, and strategic growth. The company remains dedicated to developing and distributing advanced healthcare solutions, with a growing emphasis on R&D, CDMO services, and international expansion.

Remedium Lifecare Limited , a pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs) and intermediates, has announced significant corporate changes through a postal ballot notice. The company is seeking shareholder approval for three key resolutions that could reshape its identity and leadership structure.

Proposed Name Change

The company is proposing to change its name from Remedium Lifecare Limited to Supha Pharmachem Limited. This change, if approved, would mark a new chapter for the company, although there will be no alteration to the company's core business activities. The Registrar of Companies has confirmed the availability of the new name on October 15, 2025.

New Board Appointments

Two significant board appointments are also on the agenda:

Executive Director Appointment

The company is seeking approval for the appointment of Mr. Vignesh Laxman Gawde as an Executive Director/Whole Time Director for a five-year term. Mr. Gawde, who holds an M.Sc. in Physical Chemistry from the Institute of Science, Mumbai University, is currently a Research Associate at Ajanta Pharma Ltd. If approved, he would receive a monthly compensation of Rs. 50,000.00.

Non-Executive Director and Chairman Appointment

The board is also proposing the appointment of Mr. Rambhajan Vishwakarma as a Non-Executive, Non-Independent Director and Chairman of the Board. Mr. Vishwakarma brings over 15 years of experience in banking product sales, including personal loans, mortgage loans, gold loans, and used car loans. He has previously worked as a Relationship Manager with ICICI Bank.

Voting Details

Shareholders eligible to vote on these resolutions must be on the company's register as of October 31, 2025. The e-voting period is scheduled from November 8 to December 7, 2025. Ms. Riddhi Shah has been appointed as the scrutinizer for the postal ballot process.

Financial Implications

While the proposed name change doesn't suggest any new business activities, it's worth noting that Remedium Lifecare trades in APIs and pharmaceutical intermediates in both domestic and international markets. The appointment of Mr. Gawde, with his background in physical chemistry, could potentially strengthen the company's research capabilities.

Shareholders and investors should carefully consider these proposed changes and their potential impact on the company's future direction. It's advisable to review the full postal ballot notice for complete details before making any investment decisions.